Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study.

ABSTRACT:

Background

Most patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer develop resistance or relapse. Zanidatamab is a novel, humanized, dual-HER2-targeted bispecific antibody with antitumor activity and a manageable safety profile as monotherapy in HER2-positive cancers. This trial evaluated the efficacy and safety of zanidatamab with docetaxel as first-line treatment in HER2-positive breast cancer.

Methods

Cohort 1 of this open-label, multicenter, phase Ib/II trial enrolled adult patients from China or South Korea with histologically or cytologically confirmed unresectable, locally advanced, recurrent or metastatic HER2-positive breast cancer. Patients received intravenous zanidatamab 30 mg/kg with docetaxel 75 mg/m² or a flat dose

SUBMITTER: Wang X 

PROVIDER: S-EPMC12639417 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature